Implementation of the new Siemens free light chain (FLC) kappa and lambda assays offers improvements in precision of results, linearity, antigen-excess security, and lot-to-lot consistency versus traditional methods based on polyclonal antibodies.
Preparing your laboratory for the implementation of a new tumor-marker method often requires significant preparation, because such methods typically are not easily interchangeable.
Learn how the Royal Brisbane and Women’s Hospital in Brisbane, Australia, successfully validated the N Latex FLC kappa and lambda assays and is preparing for implementation into clinical routine. Join our complimentary webinar to learn about the hospital's experience with the N Latex FLC assays, as presented from both the laboratory's and the hematologist’s perspective.
Please note: This event is intended for healthcare professionals outside of the U.S. only.
Dept of Chemical Pathology, Pathology Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia
Dr. Peter Mollee, MBBS
Dept of Hematology, Pathology Queensland, Princess Alexandra Hospital, Brisbane, Australia
The products mentioned herein are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.